AstraZeneca Adds High-Tech Biologics Bulk Manufacturing Facility In Boulder, Colorado
09/11/2015
Pam Cheng, Executive Vice-President, Operations and Information Technology at AstraZeneca, said, “The addition of the Boulder facility will support the progression of biotech drug candidates across our main therapeutic areas as we continue to bring innovative new treatments to patients. This site will play an important role in our future commercial production and give AstraZeneca and MedImmune, our global biologics research and development arm, the flexibility and capacity to meet the needs of our rapidly growing biologics portfolio.”
Over time, the LakeCentre facility, in Boulder, will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines. AstraZeneca plans to start staffing the facility immediately to support refurbishment and infrastructure improvements. Once complete, the site is expected to be operational and licensed for commercial production by late 2017, providing for additional capacity within the company’s biologics operations.
In the longer- term, this site could create up to 400 highly skilled jobs, subject to relevant approvals by the local authorities, company officials said. The facility will eventually double the biologics manufacturing capacity in the US to meet the needs of the maturing AstraZeneca pipeline. Currently biologics make up 50 percent of the company’s pipeline with more than 120 ongoing programmes, including over 30 in clinical development.
Project Announcements
Geartek Expands Corinth, Mississippi, Production Operations
05/03/2024
Bekaert Expands Van Buren, Arkansas, Production Operations
05/03/2024
ESS Technologies Expands Montgomery County, Virginia, Operations
05/02/2024
Martin’s Famous Potato Rolls and Bread Expands Franklin County, Pennsylvania, Operations
05/02/2024
StandardAero Expands Augusta, Georgia, Operations
05/02/2024
Nextracker-JM Steel Expand Leetsdale, Pennsylvania, Operations
05/01/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
Making Hybrid More Human in 2024
Q1 2024
-
20th Annual Consultants Survey: Clients Prioritize Access to Skilled Labor, Responsive State & Local Government
Q1 2024
-
Manufacturing Momentum Is Building
Q1 2024
-
Public-Private Partnerships Incentivize Industrial Development
Q1 2024